載入...
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m(2) days 1 and 2 of cycle 1 and 27 mg/m(2) days 8, 9, 15, 16, and thereafter;...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3814729/ https://ncbi.nlm.nih.gov/pubmed/24014245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-07-511170 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|